Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 361

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 361
---
                                                            —                                           —                             —                 
  Income tax benefit / (expense) (a) + (b)                                                    —                                           —                             —                 

17)Discontinued Operations

As a reminder, a termination and transition agreement was negotiated and executed, effective as of June 30, 2021 further to the Company's decision to return the rights of Lumoxiti back to AstraZeneca. Consecutively, activities related to Lumoxiti are presented as discontinued operations since October 1, 2021. As part of the termination and transition agreement, Innate and AstraZeneca agreed to share

F-82

manufacturing costs, and Innate had to pay $ 6.2 5.9 6.2

The net income from discontinued operations related to Lumoxiti as of December 31, 2023 as well as of December 31, 2024 are nil 0.13

a) Financial Performance

                                                           Year ended December 31,  
                                                           2022                     
 ────────────────────────────────────────────────────────────────────────────────────
  Revenue and other income                                                          
  Revenue from collaboration and licensing agreements      194                      
  Sales                                                    22                       
  Total revenue and other income                           216                      
  Operating expenses                                                                
  Research and development expenses                        —                        
  Selling, general and administrative expenses             ( 346)                   
  Impairment of intangible assets                          —                        
  Total operating expenses                                 ( 346)                   
  Net income (loss) from distribution agreements           —                        
  Operating income (loss)                                  ( 131)                   
  Financial income                                         —                        
  Financial expenses                                       —                        
  Net financial income (loss)                              —                        
  Net income (loss) before tax                             ( 131)                   
  Income tax expense                                       —                        
  Net income (loss) from discontinued operations           ( 131)                   

F-83

b ) Cash-Flows

                                                                    Year ended December 31,  
                                                                    2022                     
  Net cash generated from / (used in) operating activities (1)      ( 5,097)                 
  Net cash generated from / (used in) investing activities          —                        
  Net cash generated from / (used in) financing activities          —                        
  Net cash flows from discontinued operations                       ( 5,097)                 
 ─────────────────────────────────────────────────────────────────────────────────────────────

18)Commitments, contingencies and litigations

Commitments

The